MedTrace Logo

Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study

NCT05697705 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 188814085

Last updated 2024-11-21

No results posted yet for this study

Summary

This study will address specific questions concerning the additional protection of the AZ COVID-19 vaccine as a second booster dose in preventing severe COVID-19 outcomes (hospitalisation, ICU admission etc) and will provide data to inform COVID-19 vaccine booster dose recommendations.

Conditions

Interventions

OTHER

ChAdOx1 nCOV-19 vaccine (Vaxzeria)

Used as 2nd booster, 1st booster, or primary series

OTHER

BNT162b2 (Pfizer)

Used as 2nd booster, 1st booster, or primary series.

OTHER

Ad26.COV2.S (Janssen)

Used as 2nd booster, 1st booster, or primary series.

OTHER

CoronaVac (Sinovac)

Used as 2nd booster, 1st booster, or primary series.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-22
Primary Completion
2023-05-18
Completion
2023-05-18

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05697705 on ClinicalTrials.gov